WO2005112991A3 - Vaccines - Google Patents

Vaccines Download PDF

Info

Publication number
WO2005112991A3
WO2005112991A3 PCT/EP2005/005555 EP2005005555W WO2005112991A3 WO 2005112991 A3 WO2005112991 A3 WO 2005112991A3 EP 2005005555 W EP2005005555 W EP 2005005555W WO 2005112991 A3 WO2005112991 A3 WO 2005112991A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
adjuvant
antigen
complexed
metal salt
functional equivalent
Prior art date
Application number
PCT/EP2005/005555
Other languages
French (fr)
Other versions
WO2005112991A2 (en )
Inventor
Patrick Chomez
Catherine Pascaline Collignon
Mechelen Marcelle Paulette Van
Original Assignee
Glaxosmithkline Biolog Sa
Patrick Chomez
Catherine Pascaline Collignon
Mechelen Marcelle Paulette Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Abstract

The present invention provides a vaccine composition comprising the B subunit of Shiga toxin or an immunologically functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen, and further comprising an adjuvant, provided that when the adjuvant is solely a metal salt it is formulated in such a way that not more than about 50% of the antigen is adsorbed onto the metal salt. Such compositions provide an improved immune response compared to Shiga toxin or an immunologically functional equivalent thereof complexed with an antigen with no adjuvant, or an antigen alone with adjuvant.
PCT/EP2005/005555 2004-05-21 2005-05-19 Vaccines WO2005112991A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0411411.2 2004-05-21
GB0411411A GB0411411D0 (en) 2004-05-21 2004-05-21 Vaccines

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2005244615A AU2005244615A1 (en) 2004-05-21 2005-05-19 Vaccines
JP2007517101T JP2007538044T5 (en) 2005-05-19
EP20050751697 EP1761275A2 (en) 2004-05-21 2005-05-19 Adjuvanted shiga toxin b-subunit based vaccines
BRPI0511185A BRPI0511185A (en) 2004-05-21 2005-05-19 vaccine composition, use of the b subunit of a shiga toxin or immunologically functional equivalent thereof and an antigen and an adjuvant, and process for the production of a vaccine
CA 2564778 CA2564778A1 (en) 2004-05-21 2005-05-19 Vaccines
US11569177 US20080069832A1 (en) 2004-05-21 2005-05-19 Vaccines
MXPA06013386A MXPA06013386A (en) 2004-05-21 2005-05-19 Vaccines.
IL17889006A IL178890D0 (en) 2004-05-21 2006-10-26 Vaccines
NO20065304A NO20065304A (en) 2004-05-21 2006-11-20 vaccinations

Publications (2)

Publication Number Publication Date
WO2005112991A2 true WO2005112991A2 (en) 2005-12-01
WO2005112991A3 true true WO2005112991A3 (en) 2006-03-30

Family

ID=32607764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/005555 WO2005112991A3 (en) 2004-05-21 2005-05-19 Vaccines

Country Status (8)

Country Link
US (1) US20080069832A1 (en)
EP (1) EP1761275A2 (en)
KR (1) KR20070029730A (en)
CN (1) CN1956729A (en)
CA (1) CA2564778A1 (en)
GB (1) GB0411411D0 (en)
RU (1) RU2006139424A (en)
WO (1) WO2005112991A3 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534594A (en) 2005-03-31 2008-08-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Vaccine against Chlamydia infection
EP2457926B1 (en) 2005-04-29 2014-09-24 GlaxoSmithKline Biologicals S.A. Novel method for preventing or treating M. tuberculosis infection
WO2006123155A3 (en) * 2005-05-19 2007-07-19 Glaxosmithkline Biolog Sa Vaccine composition comprising b-subunit of e. coli heat toxin and an atigen and an adjuvant
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
CA2651764A1 (en) * 2006-05-09 2007-11-22 Gerald V. Quinnan Hiv-1 immunogenic compositions
CN101678091A (en) 2007-05-24 2010-03-24 葛兰素史密丝克莱恩生物有限公司 Lyophilised antigen composition
EP1938836A1 (en) * 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
WO2009126819A1 (en) 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Methods for improving the bioactivity of therapeutic ige antibodies for the treatment of disease
JP2012523379A (en) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン Immunogenic compositions and the use thereof
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
DE102009056884A1 (en) 2009-12-03 2011-06-09 Novartis Ag Vaccine adjuvants and to improved processes for the preparation thereof
DE102009056883B4 (en) * 2009-12-03 2012-08-16 Novartis Ag Vaccine adjuvants and to improved processes for the preparation thereof
JP5820390B2 (en) * 2009-12-03 2015-11-24 ノバルティス アーゲー Circulation of components in microfluidized emulsions and / or homogenization in
USRE46906E1 (en) 2009-12-03 2018-06-26 Novartis Ag Methods for producing vaccine adjuvants
CA2819298A1 (en) 2010-12-14 2012-06-21 Glaxosmithkline Biologicals S.A. Mycobacterium antigenic composition
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012658A1 (en) * 1995-03-24 2002-01-31 James A. Williams Prevention and treatment of verotoxin-induced disease
US20020081307A1 (en) * 1998-05-15 2002-06-27 Allan M. Green Verotoxin b subunit for immunization
WO2002060937A1 (en) * 2001-02-01 2002-08-08 Institut Curie Universal carrier for targeting molecules to gb3 receptor expressing cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012658A1 (en) * 1995-03-24 2002-01-31 James A. Williams Prevention and treatment of verotoxin-induced disease
US20020081307A1 (en) * 1998-05-15 2002-06-27 Allan M. Green Verotoxin b subunit for immunization
US20040013681A1 (en) * 1998-05-15 2004-01-22 Select Therapeutics, Inc. Verotoxin B subunit for immunization
WO2002060937A1 (en) * 2001-02-01 2002-08-08 Institut Curie Universal carrier for targeting molecules to gb3 receptor expressing cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HAICHEUR NACILLA ET AL: "The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization.", INTERNATIONAL IMMUNOLOGY. OCT 2003, vol. 15, no. 10, October 2003 (2003-10-01), pages 1161 - 1171, XP002353584, ISSN: 0953-8178 *
IMAI YASUYUKI ET AL: "Production of secretory immunoglobulin A against Shiga toxin-binding subunits in mice by mucosal immunization.", INFECTION AND IMMUNITY, vol. 72, no. 2, February 2004 (2004-02-01), pages 889 - 895, XP002353586, ISSN: 0019-9567 *
MORON G ET AL: "New tools for antigen delivery to the MHC class I pathway", TRENDS IN IMMUNOLOGY, ELSEVIER, RAHWAY, NJ, US, vol. 25, no. 2, February 2004 (2004-02-01), pages 92 - 97, XP004487053, ISSN: 1471-4906 *
NACILLA HAICHEUR ET AL: "The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 165, September 2000 (2000-09-01), pages 3301 - 3308, XP002187748, ISSN: 0022-1767 *
ROSS PÁDRAIG J ET AL: "Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells.", INFECTION AND IMMUNITY. MAR 2004, vol. 72, no. 3, March 2004 (2004-03-01), pages 1568 - 1579, XP002353585, ISSN: 0019-9567 *
SMITH DANIEL C ET AL: "1st class ticket to class I: protein toxins as pathfinders for antigen presentation.", TRAFFIC (COPENHAGEN, DENMARK) OCT 2002, vol. 3, no. 10, October 2002 (2002-10-01), pages 697 - 704, XP009056875, ISSN: 1398-9219 *
SUCKOW MARK A ET AL: "Stimulation of gastrointestinal antibody to Shiga toxin by orogastric immunization in mice", IMMUNOLOGY AND CELL BIOLOGY, vol. 72, no. 1, 1994, pages 69 - 74, XP009056873, ISSN: 0818-9641 *

Also Published As

Publication number Publication date Type
WO2005112991A2 (en) 2005-12-01 application
JP2007538044A (en) 2007-12-27 application
KR20070029730A (en) 2007-03-14 application
EP1761275A2 (en) 2007-03-14 application
CN1956729A (en) 2007-05-02 application
CA2564778A1 (en) 2005-12-01 application
GB0411411D0 (en) 2004-06-23 grant
US20080069832A1 (en) 2008-03-20 application
RU2006139424A (en) 2008-06-27 application

Similar Documents

Publication Publication Date Title
McCluskie et al. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA
WO2004030608A3 (en) Nanoemulsion vaccines
WO2008014979A3 (en) NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
WO2007100699A3 (en) Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
WO2005047860A3 (en) Antibodies to alpha-synuclein
Whitlock et al. Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2005081847A3 (en) Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
WO2006036550A3 (en) Listeria-based and llo-based vaccines
WO2009095226A3 (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
WO2009057763A1 (en) Novel adjuvant
WO2006041933A3 (en) Improved vaccines
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
Sela et al. Synthetic peptides with antigenic specificity for bacterial toxins
CA2634887A1 (en) Capsular saccharide conjugate vaccines against streptococcus pneumoniae
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2000050006A3 (en) Microemulsions with adsorbed macromoelecules and microparticles
Hogan Climatic and Biotic Effects of a Gamma Ray Burst near Earth
WO2006096490A3 (en) ANTI-MAdCAM ANTIBODY COMPOSITIONS
WO2009114560A3 (en) Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
WO2006103568A3 (en) NEW CLASS OF Ϝδ T CELLS ACTIVATORS AND USE THEREOF
WO2004041157A3 (en) Group b streptococcus vaccine
WO2008116219A3 (en) Uses of monoclonal antibody 8h9

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 178890

Country of ref document: IL

Ref document number: 2564778

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005244615

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200609500

Country of ref document: ZA

Ref document number: 551333

Country of ref document: NZ

Ref document number: 2006/09500

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 11569177

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/013386

Country of ref document: MX

Ref document number: 2007517101

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580016322.4

Country of ref document: CN

Ref document number: 12006502328

Country of ref document: PH

Ref document number: 06117698

Country of ref document: CO

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase in:

Ref document number: 2005244615

Country of ref document: AU

Date of ref document: 20050519

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005244615

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067025212

Country of ref document: KR

Ref document number: 3583/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005751697

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1200602096

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2006139424

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005751697

Country of ref document: EP

Ref document number: 1020067025212

Country of ref document: KR

ENP Entry into the national phase in:

Ref document number: PI0511185

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 11569177

Country of ref document: US